CY1106682T1 - Ενωση λακταμης - Google Patents

Ενωση λακταμης

Info

Publication number
CY1106682T1
CY1106682T1 CY20071100848T CY071100848T CY1106682T1 CY 1106682 T1 CY1106682 T1 CY 1106682T1 CY 20071100848 T CY20071100848 T CY 20071100848T CY 071100848 T CY071100848 T CY 071100848T CY 1106682 T1 CY1106682 T1 CY 1106682T1
Authority
CY
Cyprus
Prior art keywords
laktamis
association
methods
methyl
alaninyl
Prior art date
Application number
CY20071100848T
Other languages
Greek (el)
English (en)
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1106682T1 publication Critical patent/CY1106682T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
CY20071100848T 2000-11-17 2007-06-28 Ενωση λακταμης CY1106682T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (en) 2000-11-17 2001-11-02 Lactam compound

Publications (1)

Publication Number Publication Date
CY1106682T1 true CY1106682T1 (el) 2012-05-23

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100848T CY1106682T1 (el) 2000-11-17 2007-06-28 Ενωση λακταμης

Country Status (33)

Country Link
US (1) US20040248878A1 (https=)
EP (1) EP1353910B1 (https=)
JP (1) JP4116431B2 (https=)
KR (1) KR20030045194A (https=)
CN (2) CN100516047C (https=)
AR (1) AR031356A1 (https=)
AT (1) ATE362919T1 (https=)
AU (2) AU2002224321B2 (https=)
BR (1) BR0115424A (https=)
CA (1) CA2425497C (https=)
CY (1) CY1106682T1 (https=)
CZ (1) CZ20031340A3 (https=)
DE (1) DE60128587T2 (https=)
DK (1) DK1353910T3 (https=)
DZ (1) DZ3454A1 (https=)
EA (1) EA006919B1 (https=)
EC (1) ECSP034598A (https=)
ES (1) ES2286162T3 (https=)
HR (1) HRP20030385A2 (https=)
HU (1) HUP0301862A3 (https=)
IL (1) IL155275A0 (https=)
MX (1) MXPA03004250A (https=)
MY (1) MY141607A (https=)
NO (1) NO325217B1 (https=)
PE (1) PE20020798A1 (https=)
PL (1) PL211018B1 (https=)
PT (1) PT1353910E (https=)
SK (1) SK287794B6 (https=)
SV (1) SV2003000741A (https=)
TW (1) TWI235151B (https=)
UA (1) UA77165C2 (https=)
WO (1) WO2002040451A2 (https=)
ZA (1) ZA200303411B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
EP2133340B1 (en) 2002-12-20 2013-01-16 Glaxo Group Limited Novel benzazepine derivatives
MXPA05007485A (es) 2003-01-14 2006-01-30 Arena Pharm Inc Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia.
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
US8114886B2 (en) 2005-04-08 2012-02-14 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
US8258302B2 (en) * 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
PH12013500547A1 (en) 2010-09-22 2013-06-10 Arena Pharm Inc Modulators of the gpr119 receptor and the treatment of disorders related thereto
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
JP6319912B2 (ja) 2013-04-19 2018-05-09 国立大学法人 岡山大学 アミロイドβ蛋白質により誘発される認知障害の治療剤およびアルツハイマー病治療薬、ならびにこれらに関連する治療方法および病態解析方法
MX386419B (es) 2015-01-06 2025-03-18 Arena Pharm Inc Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
EP3939965A1 (en) 2015-06-22 2022-01-19 Arena Pharmaceuticals, Inc. Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid for use in sipi receptor-associated disorders
MA47504A (fr) 2017-02-16 2019-12-25 Arena Pharm Inc Composés et méthodes de traitement de l'angiocholite biliaire primitive
ES2987794T3 (es) 2018-06-06 2024-11-18 Arena Pharm Inc Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1
BR112022018987A2 (pt) 2020-03-26 2022-11-01 Seagen Inc Métodos de tratamento de mieloma múltiplo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
WO1999067219A1 (en) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
JP2003513958A (ja) * 1999-11-09 2003-04-15 イーライ・リリー・アンド・カンパニー β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物

Also Published As

Publication number Publication date
CA2425497A1 (en) 2002-05-23
ZA200303411B (en) 2004-08-02
CN100516047C (zh) 2009-07-22
IL155275A0 (en) 2003-11-23
SK287794B6 (sk) 2011-10-04
CZ20031340A3 (cs) 2004-06-16
JP2004521084A (ja) 2004-07-15
KR20030045194A (ko) 2003-06-09
UA77165C2 (en) 2006-11-15
CA2425497C (en) 2010-08-17
AU2432102A (en) 2002-05-27
PT1353910E (pt) 2007-08-20
JP4116431B2 (ja) 2008-07-09
WO2002040451A3 (en) 2003-08-28
EP1353910B1 (en) 2007-05-23
EA200300579A1 (ru) 2003-12-25
DE60128587D1 (de) 2007-07-05
ECSP034598A (es) 2003-06-25
BR0115424A (pt) 2003-10-21
AR031356A1 (es) 2003-09-17
CN1575282A (zh) 2005-02-02
MXPA03004250A (es) 2003-09-22
MY141607A (en) 2010-05-31
NO20032215L (no) 2003-07-16
US20040248878A1 (en) 2004-12-09
ATE362919T1 (de) 2007-06-15
TWI235151B (en) 2005-07-01
PE20020798A1 (es) 2002-09-06
AU2002224321B2 (en) 2006-10-19
DZ3454A1 (fr) 2002-05-23
PL360991A1 (en) 2004-09-20
SV2003000741A (es) 2003-01-13
HUP0301862A2 (hu) 2003-09-29
CN101624372A (zh) 2010-01-13
SK5432003A3 (en) 2004-09-08
PL211018B1 (pl) 2012-03-30
DE60128587T2 (de) 2008-01-31
EA006919B1 (ru) 2006-04-28
WO2002040451A2 (en) 2002-05-23
HUP0301862A3 (en) 2007-09-28
EP1353910A2 (en) 2003-10-22
DK1353910T3 (da) 2007-09-10
NO20032215D0 (no) 2003-05-15
ES2286162T3 (es) 2007-12-01
HRP20030385A2 (en) 2003-08-31
NO325217B1 (no) 2008-02-25

Similar Documents

Publication Publication Date Title
CY1106682T1 (el) Ενωση λακταμης
CY1106366T1 (el) Ενωση λακταμης για την αναστολη της απελευθερωσης ή της συνθεσης βητα-αμυλοειδους πεπτιδιου
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
CY1112687T1 (el) Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες
BR9902086A (pt) Formulações farmacêuticas.
CY1108067T1 (el) Υποκατεστημενα παραγωγα 2-πυριδινο-κυκλοεξανο-1,4-διαμινης
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
IT1317716B1 (it) Processo per la preparazione di perfluoropoliossialchileni conterminali ossidrilici.
DE60227718D1 (de) Verwendung von 2-Fuoro-3-Ketoestern zur Herstellung von 3-Fuoro-6,7,8,9-tetrahydro-4H-pyrimidoÄ1,2-aÜpyrimidin-4-onen
CY1105387T1 (el) Υποκατεστημενα παραγωγα 2-διαλκυλαμινοαλκυλοδιφαινθλιου
NO20063254L (no) Immunstimulerende sammensetning omfattende minst en toll-lignende reseptor 7 eller toll-lignende reseptor 8 agonist og en toll-lignende reseptor 4 agonist
TR200100895T2 (tr) Heterosiklik ikameli propanolamin türevleri, üretimi, ilaçları,kullanımı
DE60210598D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITRM20030363A0 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico diesse.
BR9713176A (pt) Benzotiofenos amorfos,métodos de preparação e métodos de uso
DE60222806D1 (de) Verfahren zur herstellung von (1,4,5)-oxadiazepinderivaten
ITMI20001695A0 (it) Procedimento per la preparazione di composizioni organico-sili-coniche.
CY1106712T1 (el) Υποκατεστημενα παραγωγα 5-αμινο-1-πεντεν-3-ολης
DE602004013011D1 (de) Haarbehandlungszusammensetzungen
DK1328275T3 (da) Substituerede 4,5-dihydro-1,2,4-triazin-3-oner, 1,2,4-triazin-3-oner og deres anvendelse som fungicider og insekticider
CY1105345T1 (el) Φαινυλαλκινια
ITTO20020747A1 (it) Composizione.
CY1110737T1 (el) Υποκατεστημενες ενωσεις 1,5-διαμινοπενταν-3-ολης
BR0011559A (pt) Processo para a preparação de derivados de 10, 11-metano benzossuberano